A case of effective use of alemtuzumab in a male patient with T-cell lymphoma


  1. Hale G., Dyer M. J., Waldmann H. et al. Remission induction in non-Hodgkin lymphoma with reshaped human monoclonal antibody CAMPATH-1H. Lancet 1988; 2 (8625): 1394-1399.
  2. Dearden С. E., Matutes E., Catovsky D. Alemtuzumab in T-cell malignancies. Med. Oncol. 2002; 19 (suppl): S27-S32.
  3. Dearden С. E., Dyer M. J., Catovsky D. et al. High remission rate in T-cell prolymphocytic leukemia with CAMPATH-1H. Blood 2001; 98(6): 1721-1726.
  4. Hainsworth J. D. Monoclonal antibody therapy in lymphoid malignancies. Oncologist 2000; 5(5): 376-384.
  5. Keating M. New drugs in hematologic malignancies. Haematologica 2001; 86(N 11, suppl.): 40-42.
  6. Воробьев А. И., Виноградова Ю. Э. В кн. Воробьев А. И. (ред.) Руководство по гематологии. М.; 2003: 57-63, 113-131.
  7. Воробьев А. И., Кременецкая А. М., Лорие Ю. Ю. "Старые" и "новые" опухоли лимфатической системы. Тер. арх. 2000; 7: 9-13.
  8. Jaffe E. S., Harris N. L., Stein H., Wordiman J. W. Pathology and genetics of tumors and of haemopoietic and lymphoid tissues. WHO classifications of tumors. Lyon: IRCS Press; 2001.
  9. Birhiray R. E., Shaw C., Brettman L. et al. Phenotypic transformation of CD52 (pos) to CD52 (neg) leukemic T-cell as a mechanism for resistance to CAMPATH-1H. Leukemia 2002; 16 (5): 861-864.

Copyright (c) 2004 Sokolov A.N., Parovichnikova E.N., Isaev V.С., Ustinova Е.N., Shavlokhov V.S., Atopkov V.A., Model S.V., Tsyba N.N., Kaplanskaya I.В., Klyasova G.A., Aleksanyan M.Z., Vishnevskaya E.S., Togonidze D.K., Mirzoyan E.E., Savchenko V.G.

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

Address of the Editorial Office:

  • Novij Zykovskij proezd, 3, 40, Moscow, 125167

Correspondence address:

  • Alabyan Street, 13/1, Moscow, 127055, Russian Federation

Managing Editor:

  • Tel.: +7 (926) 905-41-26
  • E-mail: e.gorbacheva@ter-arkhiv.ru


© 2018-2021 "Consilium Medicum" Publishing house

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies